NCYM inhibitors are a class of chemical compounds that have gained significant attention in the field of molecular biology and cancer research. These inhibitors primarily target the protein NCYM (N-Myc downstream-regulated gene 2), which plays a pivotal role in cell proliferation and cancer development. NCYM is known to be involved in the regulation of the oncogene N-Myc, a key player in the growth and proliferation of cancer cells. By inhibiting NCYM, these compounds aim to disrupt the intricate signaling pathways that promote cancer progression.
NCYM inhibitors typically involves binding to NCYM and interfering with its ability to activate downstream pathways that promote cell division and survival. This disruption of NCYM function can lead to the suppression of tumor growth, making NCYM inhibitors a promising avenue for cancer research. Researchers have been actively working on developing and optimizing NCYM inhibitors to enhance their efficacy and specificity. Understanding the structural and biochemical properties of these inhibitors is essential for their further development and research.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid induces differentiation and can downregulate MYCN. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor, alters gene expression including MYCN. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Aldehyde dehydrogenase inhibitor, shown to decrease MYCN levels in neuroblastoma cells. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
Synthetic retinoid, decreases MYCN expression in certain cell lines. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor, can lead to decreased MYCN translation. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Akt inhibitor, can reduce MYCN stability. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET bromodomain inhibitor, affects transcription of MYCN. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
DNA-damaging agent, can lead to downregulation of MYCN. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
MDM2 inhibitor, stabilizes p53, which can negatively regulate MYCN. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Histone deacetylase inhibitor, can potentially affect MYCN expression. | ||||||